Physician profile
Carrie A Steichen
NPI 1710004544
$6,892.21
in general payments reported to CMS, 2019-2025
27 companies · $679 in 2025
The $679 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $1,710 · 2021: $697 · 2022: $1,013 · 2023: $823 · 2024: $964 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,886.96 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Pain Management |
| Medtronic, INC. | $691.13 | 2021-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Accurian |
| Abbott Laboratories | $570.52 | 2019-2025 | Eterna |
| Abbvie INC. | $231.41 | 2019-2025 | Botox, Ubrelvy |
| Nevro Corp. | $214.28 | 2019-2024 | Senza |
| Medtronic USA, INC. | $196.70 | 2019-2020 | |
| Mml US, INC. | $173.26 | 2023 | Reactiv8 |
| Relievant Medsystems, INC. | $143.53 | 2022 | |
| Allergan, INC. | $94.33 | 2019-2021 | |
| Lilly USA, LLC | $80.53 | 2019-2021 | |
| Protega Pharmaceutials INC | $80.30 | 2022 | |
| Biotronik Nro, INC. | $68.51 | 2025 | Prospera |
| Fidia Pharma USA INC. | $65.48 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $56.69 | 2019 | |
| Nalu Medical, INC. | $52.65 | 2021-2025 | Nalu Neurostimulation System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $39.86 | 2025 | Euflexxa |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Globus Medical, INC. | $33.33 | 2025 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $31.57 | 2022 | |
| Averitas Pharma INC. | $26.82 | 2025 | Qutenza |
| Pfizer INC. | $25.98 | 2019-2023 | |
| Biodelivery Sciences International, INC. | $25.06 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $15.26 | 2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $13.67 | 2021 | |
| Amgen INC. | $13.48 | 2019 | |
| Stimwave Technologies Incorporated | $13.16 | 2020 | |
| Zyla Life Sciences, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Steichen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.